cagrilintide results In the REDEFINE 2 phase 3a trial involving adults with obesity and diabetes, the use of cagrilintide–semaglutide resulted in a significantly lower body weight than placebo at 68 weeks. Full trial Once-weekly cagrilintide for weight management

People report decreased appetite as early as one week, and significantly less hunger, reduced eating, and fewer cravings starting between weeks 3 and 8

Addressing underlying causes is essential: Dietary modification and supplementation for vegans/vegetarians Management of gastrointestinal disorders affecting absorption Screening for coeliac disease if indicated Review of medications that may contribute to deficiencypatients should not stop prescribed medications such as metformin or proton pump inhibitors without consulting their doctor For patients on long-term metformin, the MHRA recommends considering vitamin B12 testing in those with symptoms or risk factors for deficiency, with periodic monitoring in at-risk groups

For body recomposition, the performance protocol (10 mg/week) accelerates results

Lyophilized peptides tolerate freezing without damage

AOD-9604 is a synthetic peptide fragment that has attracted scientific interest within metabolic research, cellular signalling investigations and energy regulation studies